SRPT
Income statement / Annual
Last year (2023), Sarepta Therapeutics, Inc.'s total revenue was $1.24 B,
an increase of 33.26% from the previous year.
In 2023, Sarepta Therapeutics, Inc.'s net income was -$535.98 M.
See Sarepta Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$1.24 B
|
$933.01 M
|
$701.89 M
|
$540.10 M
|
$380.83 M
|
$301.03 M
|
$154.58 M
|
$5.42 M
|
$1.25 M
|
$9.76 M
|
| Cost of Revenue |
$150.34 M |
$139.99 M |
$97.05 M |
$63.38 M |
$56.59 M |
$34.19 M |
$7.35 M |
$130,000.00 |
$146.19 M |
$94.10 M |
| Gross Profit |
$1.09 B |
$793.02 M |
$604.84 M |
$476.72 M |
$324.25 M |
$266.84 M |
$147.23 M |
$5.29 M |
-$144.94 M |
-$84.35 M |
| Gross Profit Ratio |
0.88 |
0.85 |
0.86 |
0.88 |
0.85 |
0.89 |
0.95 |
0.98 |
-115.68 |
-8.64 |
| Research and Development
Expenses |
$877.39 M
|
$877.09 M
|
$771.18 M
|
$722.34 M
|
$560.91 M
|
$401.84 M
|
$166.71 M
|
$188.27 M
|
$146.39 M
|
$94.23 M
|
| General & Administrative
Expenses |
$481.87 M
|
$451.42 M
|
$282.66 M
|
$317.88 M
|
$284.81 M
|
$209.98 M
|
$119.85 M
|
$81.20 M
|
$75.04 M
|
$49.32 M
|
| Selling & Marketing
Expenses |
$28.60 M
|
$14.60 M
|
$7.70 M
|
$0.00
|
$0.00
|
-$2.22 M
|
$2.83 M
|
$2.55 M
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$481.87 M
|
$451.42 M
|
$282.66 M
|
$317.88 M
|
$284.81 M
|
$207.76 M
|
$122.68 M
|
$83.75 M
|
$75.04 M
|
$49.32 M
|
| Other Expenses |
$1.56 M |
$714,000.00 |
$706,000.00 |
$662,000.00 |
$849,000.00 |
-$656,000.00 |
$1.98 M |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$1.36 B |
$1.33 B |
$1.05 B |
$1.04 B |
$846.57 M |
$610.47 M |
$290.44 M |
$272.02 M |
$221.44 M |
$143.55 M |
| Cost And Expenses |
$1.51 B |
$1.47 B |
$1.15 B |
$1.10 B |
$903.16 M |
$644.66 M |
$297.80 M |
$272.15 M |
$221.44 M |
$143.55 M |
| Interest Income |
$85.97 M |
$16.49 M |
$354,000.00 |
$2.97 M |
$7.24 M |
$6.81 M |
$1.81 M |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$22.01 M |
$53.25 M |
$63.53 M |
$59.95 M |
$30.67 M |
$33.71 M |
$5.78 M |
-$535,000.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$58.89 M
|
$54.60 M
|
$49.34 M
|
$39.74 M
|
$30.55 M
|
$12.25 M
|
$8.09 M
|
$5.61 M
|
$5.25 M
|
$3.69 M
|
| EBITDA |
-$267.82 M
|
-$473.54 M
|
-$412.12 M
|
-$529.28 M
|
-$469.42 M
|
-$342.76 M
|
-$238.73 M
|
-$266.73 M
|
-$220.18 M
|
-$131.01 M
|
| EBITDA Ratio |
-0.22 |
-0.51 |
-0.59 |
-0.98 |
-1.23 |
-1.14 |
-1.54 |
-49.2 |
-175.73 |
-13.43 |
| Operating Income Ratio
|
-0.22
|
-0.57
|
-0.64
|
-1.04
|
-1.37
|
-1.14
|
-1.11
|
-49.2
|
-175.73
|
-13.71
|
| Total Other
Income/Expenses Net |
-$252.27 M
|
-$153.76 M
|
$30.76 M
|
$11.10 M
|
-$191.56 M
|
$10.14 M
|
$96.57 M
|
-$2.55 M
|
$154,000.00
|
-$2.78 M
|
| Income Before Tax |
-$520.10 M |
-$689.96 M |
-$418.95 M |
-$553.07 M |
-$713.88 M |
-$362.61 M |
-$48.63 M |
-$267.27 M |
-$220.03 M |
-$135.79 M |
| Income Before Tax Ratio
|
-0.42
|
-0.74
|
-0.6
|
-1.02
|
-1.87
|
-1.2
|
-0.31
|
-49.3
|
-175.6
|
-13.92
|
| Income Tax Expense |
$15.88 M |
$13.53 M |
-$168,000.00 |
$1.06 M |
$1.20 M |
-$692,000.00 |
$2.06 M |
-$7.62 M |
-$5.25 M |
-$1.69 M |
| Net Income |
-$535.98 M |
-$703.49 M |
-$418.78 M |
-$554.13 M |
-$715.08 M |
-$361.92 M |
-$50.69 M |
-$267.27 M |
-$220.03 M |
-$135.79 M |
| Net Income Ratio |
-0.43 |
-0.75 |
-0.6 |
-1.03 |
-1.88 |
-1.2 |
-0.33 |
-49.3 |
-175.6 |
-13.92 |
| EPS |
-5.8 |
-8.03 |
-5.15 |
-7.11 |
-9.71 |
-5.46 |
-0.86 |
-5.49 |
-5.2 |
-3.39 |
| EPS Diluted |
-5.8 |
-8.03 |
-5.15 |
-7.11 |
-9.71 |
-5.46 |
-0.86 |
-5.49 |
-5.2 |
-3.39 |
| Weighted Average Shares
Out |
$92.40 M
|
$87.56 M
|
$81.26 M
|
$77.96 M
|
$73.62 M
|
$66.25 M
|
$58.82 M
|
$48.68 M
|
$42.29 M
|
$40.03 M
|
| Weighted Average Shares
Out Diluted |
$92.40 M
|
$87.56 M
|
$81.26 M
|
$77.96 M
|
$73.62 M
|
$66.25 M
|
$58.82 M
|
$48.70 M
|
$42.29 M
|
$40.03 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
